Inoviq Ltd has released a press release.
BARD1 Signs Option Agreement for Type 3C Diabetes Test
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Inoviq
- Positive Results Evaluation of EXO-NET in Pancreatic Cancer
- Appendix 4D and Half-year financial report
- Commencement of Legal Proceedings Against BARD1
- Excellent SubB2M Breast Cancer Test Data
- Outstanding SubB2M Ovarian Cancer Test Data
Later from Inoviq
- Positive Results from the BARD1 Autoantibody Assay
- Appendix 4C and Quarterly Activities Report
- BARD1 Launches its RUO EXO-NET Product
- BARD1 EXO-NET Exosome Data Presented at ISEV2021 Conference
- BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test
Follow Inoviq into a list and get an email when it puts out news.
Follow Inoviq